Artemether-lumefantrine + ruxolitinib

Artemether-lumefantrine + ruxolitinib is a combination therapy under investigation for the treatment of uncomplicated malaria, particularly caused by *Plasmodium falciparum*. Artemether and lumefantrine are antimalarial agents; artemether is an artemisinin derivative that acts rapidly against blood-stage parasites, while lumefantrine has a longer half-life and helps clear residual parasites. Ruxolitinib is a Janus kinase (JAK) inhibitor primarily used in myeloproliferative disorders but here is being studied for its potential to modulate immune responses during malaria infection by inhibiting type I interferon signaling through STAT3 inhibition. The combination aims to enhance antimalarial efficacy and potentially improve immune-mediated parasite clearance[1][2][4].